Taken together, the studies above point to PKR as a hub for co-morbidity and an attractive target for the treatment of metabolic diseases, cardiovascular diseases, neurodegenerative diseases, inflammation, and cancer. The gene discussed is EIF2AK2; the disease is Other metabolic disease.